Transcenta Holding Limited (HKG:6628)

Hong Kong · Delayed Price · Currency is HKD

1.480

-0.020 (-1.33%)

Jun 18, 2026, 11:58 AM HKT

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
The Discovering, Developing, Manufacturing and Commercializing Novel Drugs	7.44M	11.26M	53.85M	101.89M	50.24M
The Discovering, Developing, Manufacturing and Commercializing Novel Drugs Growth	-33.98%	-79.09%	-47.15%	102.80%	-37.96%
Total	7.44M	11.26M	53.85M	101.89M	50.24M
Total Growth	-33.98%	-79.09%	-47.15%	102.80%	-37.96%

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019
Chinese Mainland	6.63M	10.14M	-	-	-
Chinese Mainland Growth	-34.63%	-	-	-	-
United States of America	808.00K	970.00K	-	-	-
United States of America Growth	-16.70%	-	-	-	-
Others	-	153.00K	-	-	-
PRC	-	-	53.85M	101.89M	50.24M
PRC Growth	-	-	-47.15%	102.80%	-37.96%
Total	7.44M	11.26M	53.85M	101.89M	50.24M
Total Growth	-33.98%	-79.09%	-47.15%	102.80%	-37.96%